CSL shares gained 3.3% to A$171.91 on Thursday, extending a post-earnings rally into a second consecutive session after the company reported its full-year FY26 financial results earlier in the week.
The broader S&P/ASX 200 index added 0.2%, with CSL contributing one of the largest gains to the benchmark. The company’s results came in slightly ahead of revised analyst expectations, reinforcing investor confidence in its operational performance.
For the fiscal year ended June 30, CSL reported total revenue of US$15.8 billion and underlying net profit after tax and amortisation of US$3.1 billion. The company also announced a new A$1.1 billion on-market share buyback program, signaling confidence in its cash generation and capital allocation strategy.
FY27 guidance calls for underlying profit growth of approximately 5%, providing a near-term outlook that aligns with analyst projections. Analysts highlighted improving trends in the core plasma business and cost savings of about US$176 million, which exceeded initial targets. The separation of the Seqirus influenza vaccines division was cited as a strategic move that enhances operational flexibility.
Brokerage firms responded with upward revisions to price targets. UBS raised its 12-month target to A$181 from A$158 while maintaining a Buy rating. CLSA lifted its Outperform target to A$180 from A$130, and Morgan Stanley maintained a constructive target of A$172. The upgrades reflect growing optimism about CSL’s growth trajectory and margin performance.
